Navigation Links
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
Date:9/17/2013

.D., Chief Medical Officer at arGEN-X. "ARGX-111 is an excellent example of how our suite of antibody technologies enables us to generate exciting development candidates with multiple modes of action within a single therapeutic entity."

Ahmad Awada, M.D., Ph.D. of the Jules Bordet Institute, Brussels, Belgium, and Principal Investigator of the study, commented further: "The field of c-Met inhibition is one that offers significant promise in the fight against cancer. Therefore, we are very excited to be involved in the first ever clinical trial with ARGX-111, a potentially best-in-class molecule for the treatment of a broad range of solid and hematological cancers."

About the ARGX-111 Phase Ib Trial

The Phase Ib study being undertaken by arGEN-X includes an adaptive dose escalation scheme, to be followed by a safety cohort expansion.  Approximately 35 patients will be enrolled by a consortium of leading academic institutions in Belgium. In addition to traditional clinical and PK endpoints, biomarkers critical to understanding the effect of ARGX-111 on c-Met biology will be researched during the course of the trial.

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

arGEN-X' SIMPLE Antibody™ platform generates an unprecedented diversity of high quality human antibodies, enabling optimal product choice. SIMPLE Antibodies™ are able to address and modulate any disease target
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... SAN DIEGO , Nov. 18, 2014 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that it filed an Investigational New Drug ... Administration (FDA) on Friday, November 14, 2014.  ... development of a patented formulation of the currently ...
(Date:11/18/2014)...   Rio Grande Valley Health Information Exchange (RGV ... Health Science Center at Houston (UTHealth)  School of Public ... selected Wellcentive,s suite of population health management solutions and ... to partner with hospitals and clinics in the region ... uninsured patient populations, initially focusing on the care of ...
(Date:11/18/2014)... , Nov. 17, 2014   Headquartered ... Inc. (OTC: GWPC) is a diversified company.  WholeHEALTH ... convenience of advanced technology and proven expertise of ... business of health and wellness.  WholeHEALTH Products, comprehensive ... doctors, clinics and healthcare centers, and 8 retail ...
Breaking Medicine Technology:HedgePath Pharmaceuticals Files IND Application 2HedgePath Pharmaceuticals Files IND Application 3HedgePath Pharmaceuticals Files IND Application 4Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 2Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 3Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 4WholeHEALTH Product Inc. to File FDA Emergency Use Approval (EUA) for PCR Rapid Ebola Test 2
... , , LANSING, Mich., Dec. 1 Neogen ... acquired the BioKits food safety business of San Diego, Calif.-based ... test kits for food allergens, meat and fish speciation, and ... acquisition of Tepnel Life Sciences plc in April 2009. Gen-Probe ...
... 1 CEL-SCI Corporation (NYSE Amex: CVM ), a ... for the prevention and treatment of infectious diseases, announced today ... Research Organization (CRO) to run CEL-SCI,s upcoming Phase III clinical ... Company,s lead product candidate, Multikine®. This CRO is considered ...
Cached Medicine Technology:Neogen Acquires Gen-Probe's BioKits Food Safety Business 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3
(Date:11/18/2014)... Cristcot Inc., a global life ... of specialized drug delivery systems, today announced that ... patent for the technology, which encompasses the company’s ... The patent was awarded to the inventor Jennifer ... assigned to Cristcot Inc. The patented technology, titled ...
(Date:11/18/2014)... Steven Reinberg HealthDay Reporter ... with the abnormal heartbeat known as atrial fibrillation who ... bleeding and blood clots, according to a new study. ... took a blood thinner along with one of these ... (Motrin), naproxen (Aleve) and celecoxib (Celebrex). "If ...
(Date:11/18/2014)... Recently, BellasDress has announced the launch of ... workers and using comfortable fabrics, the new styles of prom ... variety of wonderful holiday gifts in a variety of colors ... prom dresses, and they are created by top designers,” said ... absolutely great addition to our sales team and more than ...
(Date:11/18/2014)... Sometimes at inopportune times during hectic ... like unforeseen error messages or paper jams. This ... find another printer and they don’t know who is ... likely tied up with other mission-critical projects in their ... Electronic Systems, Inc. (ESI) comes in. Since ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. ... a severe abusive head trauma before the age of 5 ... study. In addition, among those who survive severe ... study found. Abusive head trauma includes shaken baby syndrome, ... head injuries, according to background information in the study. ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Some Painkillers Tied to Bleeding Risk in Those With Abnormal Heartbeat 2Health News:85 New Models Of White Prom Dresses From BellasDress.com Online For Sale 2Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4
... Nov. 1 Perrigo Company,(Nasdaq: PRGO ; ... Perrigo,s partner for store brand OTC 20mg Omeprazole ... AstraZeneca (the,manufacturer of Prilosec OTC(R)) involving three Orange ... product. While terms and conditions of the,agreement have ...
... Nov. 1 MannKind Corporation,(Nasdaq: MNKD ), focused on ... that it will present at,the following conferences: * The ... Tuesday November 6, 2007 at 2:20 PM ... New York, NY., * The CIBC 18th Annual ...
... American Diabetes Month, HARRISBURG, Pa., Nov. 1 ... Health Dr. Calvin Johnson today urged,Pennsylvanians to adopt healthy ... diabetes., Diabetes is a chronic disease that affects ... in Pennsylvania., "Diabetes is a serious, public health ...
... Statement by James Wagoner on the $28 ... Nov. 1 The following is a,statement ... increase in abstinence-only,program funding:, Today, we ... committee report includes the full $28 million,increase ...
... InfoLogix, Inc. (Nasdaq:,IFLG), a leading technology provider ... industries, will release its financial results,for the Third ... 8th,2007. Following the press release, President and Chief ... Roberts will host a conference,call with the financial ...
... Edwards Lifesciences,Corporation (NYSE: EW ), a ... cardiovascular disease, is scheduled to participate in the,Southern ... Newport,Beach, California on Wednesday, November 7, 2007. ... Investor,Relations, is scheduled to speak to conference attendees ...
Cached Medicine News:Health News:Perrigo Announces that Dexcel's Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval 2Health News:Perrigo Announces that Dexcel's Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval 3Health News:Health Secretary Promotes Awareness of Diabetes, Urges Healthy Habits 2Health News:Democrats Cave on Sex Education - Again 2Health News:InfoLogix to Report Third Quarter and Nine Month Financial Results on November 8, 2007 2Health News:Edwards Lifesciences to Present at the Southern California Investor Conference 2
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Ties improve torso fit and transfer weight to waist and hips. Ties are 1"W cotton woven for flexibility and sewn at an angle across the full width of the two back sections for durability....
Ties improve torso fit and transfer weight to waist and hips. Ties are 1"W cotton woven for flexibility and sewn at an angle across the full width of the two back sections for durability....
Hip-hugging design transfers weight from shoulders to the hips. Crisscross shoulder design provides snug and comfortable upper torso fit while preventing apron from slipping off shoulders....
Medicine Products: